시장보고서
상품코드
1275457

세계의 아토피 피부염 치료제 시장(2023-2027년)

Global Atopic Dermatitis Drugs Market 2023-2027

발행일: | 리서치사: TechNavio | 페이지 정보: 영문 162 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

아토피 피부염 치료제 시장을 모니터링했으며, 2022-2027년에 47억 2,019만 달러의 증가가 전망되며, 예측 기간 중 9.28%의 CAGR로 성장할 것으로 예측되고 있습니다.

아토피 피부염 치료제 시장에 관한 전체적인 분석, 시장 규모와 예측, 동향, 성장 촉진요인·과제 및 약 25개 벤더를 다룬 벤더 분석을 시행하고 있습니다.

현재의 시장 시나리오, 최신 동향과 촉진요인, 시장 전체의 환경에 관한 최신 분석을 제공하고 있습니다. 아토피 피부염의 높은 유병률, 의료비의 증가, 강력한 연구개발 파이프라인이 시장을 촉진하고 있습니다.

이 조사에서는 향후 수년간 아토피 피부염 치료제 시장의 성장을 촉진하는 주요 이유의 하나로 전략적 파트너십과 인수를 들고 있습니다. 또한 지정학적 불확실성이나 아토피 피부염의 인지도를 높이기 위한 프로그램은 시장의 큰 수요로 연결될 것으로 생각되고 있습니다.

목차

제1장 주요 요약

  • 시장 개요

제2장 시장 구도

  • 시장 에코시스템

제3장 시장 규모

  • 시장의 정의
  • 시장 부문 분석
  • 시장 규모 2022
  • 시장 전망 2022-2027

제4장 시장 규모 실적

  • 세계의 아토피 피부염 치료제 시장 2017-2021
  • 투여 경로 부문 분석 2017-2021
  • 약물 클래스 부문 분석 2017-2021
  • 지역별 부문 분석 2017-2021
  • 국가별 부문 분석 2017-2021

제5장 Five forces 분석

  • Five Forces 요약
  • 구매자의 교섭력
  • 공급 기업의 교섭력
  • 신규 진출업체의 위협
  • 대체품의 위협
  • 경쟁의 위협
  • 시장 현황

제6장 시장 세분화 : 투여 경로별

  • 시장 부문
  • 비교 : 투여 경로별
  • 경구 : 시장 규모와 예측 2022-2027
  • 국소 : 시장 규모와 예측 2022-2027
  • 주사 가능 : 시장 규모와 예측 2022-2027
  • 시장 기회 : 투여 경로별

제7장 시장 세분화 약물 클래스별

  • 시장 부문
  • 비교 약물 클래스별
  • 생물제제 : 시장 규모와 예측 2022-2027
  • PDE4 저해제 : 시장 규모와 예측 2022-2027
  • 코르티코스테로이드 : 시장 규모와 예측 2022-2027
  • 칼시뉴린 저해제 : 시장 규모와 예측 2022-2027
  • 시장 기회 약물 클래스별

제8장 고객 상황

  • 고객 상황의 개요

제9장 지역별 상황

  • 지역별 세분화
  • 지역별 비교
  • 북미 : 시장 규모와 예측 2022-2027
  • 유럽 : 시장 규모와 예측 2022-2027
  • 아시아 : 시장 규모와 예측 2022-2027
  • 세계의 기타 지역 : 시장 규모와 예측 2022-2027
  • 미국 : 시장 규모와 예측 2022-2027
  • 캐나다 : 시장 규모와 예측 2022-2027
  • 독일 : 시장 규모와 예측 2022-2027
  • 영국 : 시장 규모와 예측 2022-2027
  • 중국 : 시장 규모와 예측 2022-2027
  • 시장 기회 : 지역별

제10장 촉진요인, 과제 및 동향

  • 시장 촉진요인
  • 시장이 해결해야 할 과제
  • 촉진요인과 과제의 영향
  • 시장 동향

제11장 벤더 구도

  • 개요
  • 벤더 구도
  • 혼란의 상황
  • 업계의 리스크

제12장 벤더 분석

  • 대상 벤더
  • 벤더의 시장 포지셔닝
  • AbbVie Inc.
  • Arcutis Biotherapeutics Inc.
  • Bausch Health Co. Inc.
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • Evelo Biosciences Inc.
  • Galderma SA
  • Incyte Corp.
  • LEO Pharma AS
  • Maruho Co. Ltd.
  • Novartis AG
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Viatris Inc.

제13장 부록

KSA 23.06.05

Technavio has been monitoring the atopic dermatitis drugs market and is forecast to grow by USD 4720.19 mn during 2022-2027, accelerating at a CAGR of 9.28% during the forecast period. Our report on the atopic dermatitis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of atopic dermatitis, increasing healthcare expenditure, and strong R&D pipeline.

Technavio's atopic dermatitis drugs market is segmented as below:

By Route of Administration

  • Oral
  • Topical
  • Injectable

By Drug Class

  • Biologics
  • PDE4 inhibitors
  • Corticosteroids
  • Calcineurin inhibitors

By Geography

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies strategic partnerships and acquisitions as one of the prime reasons driving the atopic dermatitis drugs market growth during the next few years. Also, geopolitical uncertainties and programs to promote awareness of atopic dermatitis will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the atopic dermatitis drugs market covers the following areas:

  • Atopic dermatitis drugs market sizing
  • Atopic dermatitis drugs market forecast
  • Atopic dermatitis drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading atopic dermatitis drugs market vendors that include AbbVie Inc., Arcutis Biotherapeutics Inc., Asana BioSciences LLC, Astellas Pharma Inc., Bausch Health Co. Inc., Bayer AG, Bristol Myers Squibb Co., Dermavant Sciences Inc., Eli Lilly and Co., Evelo Biosciences Inc., Galderma SA, Incyte Corp., LEO Pharma AS, Maruho Co. Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Viatris Inc., and BiomX Inc. Also, the atopic dermatitis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market by Geography
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027
  • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global atopic dermatitis drugs market 2017 - 2021
  • Exhibit 18: Historic Market Size - Data Table on global atopic dermatitis drugs market 2017 - 2021 ($ million)
  • 4.2 Route of Administration Segment Analysis 2017 - 2021
  • Exhibit 19: Historic Market Size - Route of Administration Segment 2017 - 2021 ($ million)
  • 4.3 Drug Class Segment Analysis 2017 - 2021
  • Exhibit 20: Historic Market Size - Drug Class Segment 2017 - 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 - 2021
  • Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 - 2021
  • Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Route of Administration

  • 6.1 Market segments
  • Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
  • Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)
  • 6.2 Comparison by Route of Administration
  • Exhibit 32: Chart on Comparison by Route of Administration
  • Exhibit 33: Data Table on Comparison by Route of Administration
  • 6.3 Oral - Market size and forecast 2022-2027
  • Exhibit 34: Chart on Oral - Market size and forecast 2022-2027 ($ million)
  • Exhibit 35: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
  • Exhibit 36: Chart on Oral - Year-over-year growth 2022-2027 (%)
  • Exhibit 37: Data Table on Oral - Year-over-year growth 2022-2027 (%)
  • 6.4 Topical - Market size and forecast 2022-2027
  • Exhibit 38: Chart on Topical - Market size and forecast 2022-2027 ($ million)
  • Exhibit 39: Data Table on Topical - Market size and forecast 2022-2027 ($ million)
  • Exhibit 40: Chart on Topical - Year-over-year growth 2022-2027 (%)
  • Exhibit 41: Data Table on Topical - Year-over-year growth 2022-2027 (%)
  • 6.5 Injectable - Market size and forecast 2022-2027
  • Exhibit 42: Chart on Injectable - Market size and forecast 2022-2027 ($ million)
  • Exhibit 43: Data Table on Injectable - Market size and forecast 2022-2027 ($ million)
  • Exhibit 44: Chart on Injectable - Year-over-year growth 2022-2027 (%)
  • Exhibit 45: Data Table on Injectable - Year-over-year growth 2022-2027 (%)
  • 6.6 Market opportunity by Route of Administration
  • Exhibit 46: Market opportunity by Route of Administration ($ million)
  • Exhibit 47: Data Table on Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Drug Class

  • 7.1 Market segments
  • Exhibit 48: Chart on Drug Class - Market share 2022-2027 (%)
  • Exhibit 49: Data Table on Drug Class - Market share 2022-2027 (%)
  • 7.2 Comparison by Drug Class
  • Exhibit 50: Chart on Comparison by Drug Class
  • Exhibit 51: Data Table on Comparison by Drug Class
  • 7.3 Biologics - Market size and forecast 2022-2027
  • Exhibit 52: Chart on Biologics - Market size and forecast 2022-2027 ($ million)
  • Exhibit 53: Data Table on Biologics - Market size and forecast 2022-2027 ($ million)
  • Exhibit 54: Chart on Biologics - Year-over-year growth 2022-2027 (%)
  • Exhibit 55: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
  • 7.4 PDE4 inhibitors - Market size and forecast 2022-2027
  • Exhibit 56: Chart on PDE4 inhibitors - Market size and forecast 2022-2027 ($ million)
  • Exhibit 57: Data Table on PDE4 inhibitors - Market size and forecast 2022-2027 ($ million)
  • Exhibit 58: Chart on PDE4 inhibitors - Year-over-year growth 2022-2027 (%)
  • Exhibit 59: Data Table on PDE4 inhibitors - Year-over-year growth 2022-2027 (%)
  • 7.5 Corticosteroids - Market size and forecast 2022-2027
  • Exhibit 60: Chart on Corticosteroids - Market size and forecast 2022-2027 ($ million)
  • Exhibit 61: Data Table on Corticosteroids - Market size and forecast 2022-2027 ($ million)
  • Exhibit 62: Chart on Corticosteroids - Year-over-year growth 2022-2027 (%)
  • Exhibit 63: Data Table on Corticosteroids - Year-over-year growth 2022-2027 (%)
  • 7.6 Calcineurin inhibitors - Market size and forecast 2022-2027
  • Exhibit 64: Chart on Calcineurin inhibitors - Market size and forecast 2022-2027 ($ million)
  • Exhibit 65: Data Table on Calcineurin inhibitors - Market size and forecast 2022-2027 ($ million)
  • Exhibit 66: Chart on Calcineurin inhibitors - Year-over-year growth 2022-2027 (%)
  • Exhibit 67: Data Table on Calcineurin inhibitors - Year-over-year growth 2022-2027 (%)
  • 7.7 Market opportunity by Drug Class
  • Exhibit 68: Market opportunity by Drug Class ($ million)
  • Exhibit 69: Data Table on Market opportunity by Drug Class ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 71: Chart on Market share by geography 2022-2027 (%)
  • Exhibit 72: Data Table on Market share by geography 2022-2027 (%)
  • 9.2 Geographic comparison
  • Exhibit 73: Chart on Geographic comparison
  • Exhibit 74: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2022-2027
  • Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • 9.4 Europe - Market size and forecast 2022-2027
  • Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • 9.5 Asia - Market size and forecast 2022-2027
  • Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
  • Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • 9.7 US - Market size and forecast 2022-2027
  • Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%)
  • 9.8 Canada - Market size and forecast 2022-2027
  • Exhibit 95: Chart on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 96: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 97: Chart on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibit 98: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • 9.9 Germany - Market size and forecast 2022-2027
  • Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • 9.10 UK - Market size and forecast 2022-2027
  • Exhibit 103: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 104: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 105: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibit 106: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • 9.11 China - Market size and forecast 2022-2027
  • Exhibit 107: Chart on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 108: Data Table on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 109: Chart on China - Year-over-year growth 2022-2027 (%)
  • Exhibit 110: Data Table on China - Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity by geography
  • Exhibit 111: Market opportunity by geography ($ million)
  • Exhibit 112: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 113: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 115: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 116: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 117: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 118: Matrix on vendor position and classification
  • 12.3 AbbVie Inc.
  • Exhibit 119: AbbVie Inc. - Overview
  • Exhibit 120: AbbVie Inc. - Product / Service
  • Exhibit 121: AbbVie Inc. - Key news
  • Exhibit 122: AbbVie Inc. - Key offerings
  • 12.4 Arcutis Biotherapeutics Inc.
  • Exhibit 123: Arcutis Biotherapeutics Inc. - Overview
  • Exhibit 124: Arcutis Biotherapeutics Inc. - Product / Service
  • Exhibit 125: Arcutis Biotherapeutics Inc. - Key offerings
  • 12.5 Bausch Health Co. Inc.
  • Exhibit 126: Bausch Health Co. Inc. - Overview
  • Exhibit 127: Bausch Health Co. Inc. - Business segments
  • Exhibit 128: Bausch Health Co. Inc. - Key news
  • Exhibit 129: Bausch Health Co. Inc. - Key offerings
  • Exhibit 130: Bausch Health Co. Inc. - Segment focus
  • 12.6 Bristol Myers Squibb Co.
  • Exhibit 131: Bristol Myers Squibb Co. - Overview
  • Exhibit 132: Bristol Myers Squibb Co. - Product / Service
  • Exhibit 133: Bristol Myers Squibb Co. - Key news
  • Exhibit 134: Bristol Myers Squibb Co. - Key offerings
  • 12.7 Eli Lilly and Co.
  • Exhibit 135: Eli Lilly and Co. - Overview
  • Exhibit 136: Eli Lilly and Co. - Product / Service
  • Exhibit 137: Eli Lilly and Co. - Key offerings
  • 12.8 Evelo Biosciences Inc.
  • Exhibit 138: Evelo Biosciences Inc. - Overview
  • Exhibit 139: Evelo Biosciences Inc. - Product / Service
  • Exhibit 140: Evelo Biosciences Inc. - Key offerings
  • 12.9 Galderma SA
  • Exhibit 141: Galderma SA - Overview
  • Exhibit 142: Galderma SA - Product / Service
  • Exhibit 143: Galderma SA - Key news
  • Exhibit 144: Galderma SA - Key offerings
  • 12.10 Incyte Corp.
  • Exhibit 145: Incyte Corp. - Overview
  • Exhibit 146: Incyte Corp. - Product / Service
  • Exhibit 147: Incyte Corp. - Key offerings
  • 12.11 LEO Pharma AS
  • Exhibit 148: LEO Pharma AS - Overview
  • Exhibit 149: LEO Pharma AS - Business segments
  • Exhibit 150: LEO Pharma AS - Key offerings
  • Exhibit 151: LEO Pharma AS - Segment focus
  • 12.12 Maruho Co. Ltd.
  • Exhibit 152: Maruho Co. Ltd. - Overview
  • Exhibit 153: Maruho Co. Ltd. - Product / Service
  • Exhibit 154: Maruho Co. Ltd. - Key offerings
  • 12.13 Novartis AG
  • Exhibit 155: Novartis AG - Overview
  • Exhibit 156: Novartis AG - Business segments
  • Exhibit 157: Novartis AG - Key offerings
  • Exhibit 158: Novartis AG - Segment focus
  • 12.14 Otsuka Holdings Co. Ltd.
  • Exhibit 159: Otsuka Holdings Co. Ltd. - Overview
  • Exhibit 160: Otsuka Holdings Co. Ltd. - Business segments
  • Exhibit 161: Otsuka Holdings Co. Ltd. - Key offerings
  • Exhibit 162: Otsuka Holdings Co. Ltd. - Segment focus
  • 12.15 Pfizer Inc.
  • Exhibit 163: Pfizer Inc. - Overview
  • Exhibit 164: Pfizer Inc. - Product / Service
  • Exhibit 165: Pfizer Inc. - Key news
  • Exhibit 166: Pfizer Inc. - Key offerings
  • 12.16 Sanofi SA
  • Exhibit 167: Sanofi SA - Overview
  • Exhibit 168: Sanofi SA - Business segments
  • Exhibit 169: Sanofi SA - Key news
  • Exhibit 170: Sanofi SA - Key offerings
  • Exhibit 171: Sanofi SA - Segment focus
  • 12.17 Viatris Inc.
  • Exhibit 172: Viatris Inc. - Overview
  • Exhibit 173: Viatris Inc. - Business segments
  • Exhibit 174: Viatris Inc. - Key offerings
  • Exhibit 175: Viatris Inc. - Segment focus

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 176: Inclusions checklist
  • Exhibit 177: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 178: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 179: Research methodology
  • Exhibit 180: Validation techniques employed for market sizing
  • Exhibit 181: Information sources
  • 13.5 List of abbreviations
  • Exhibit 182: List of abbreviations
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제